Share price · AZN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AZN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+7.0%
- 3 Aug 2026-6.9%
- 10 Jul 2026-3.9%
- 9 Jul 2026-5.7%
- 2 Jul 2026+6.1%
- 1 Jul 2026-3.0%
- 27 Mar 2026+2.7%
- 11 Feb 2026+5.9%
- Day beforeAstraZeneca: FINAL RESULTS
- 10 Feb 2026+2.9%
- 20 Jan 2026-4.7%
Share of unusual movement by asset
For each asset, the share of AZN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(114 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | BTKSmall molecule | Diffuse Large B-Cell LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia Relapsed/Refractory Chronic Lymphocytic Leukemia | |
albuterol / budesonide(Airsupra) | Approved | Beta-2 adrenergic receptor · Glucocorticoid receptorCombination | Asthma |
| Approved | AromataseSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody | Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis | |
Baxdrostat(Baxfendy) | Approved | Aldosterone synthase (CYP11B2)Small molecule | HypertensionHeart FailureChronic Kidney Disease |
Benralizumab(Fasenra) | Approved | IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody | Asthma |
Budesonide(Pulmicort) | Approved | Glucocorticoid receptor agonistSmall molecule | Asthma |
| Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorCombination | Chronic Obstructive Pulmonary DiseaseAsthma | |
Budesonide/glycopyrrolate/formoterol fumarate(Breztri Aerosphere) | Approved | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma |
Camizestrant(Etcamah) | Approved | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Approved | AKT (inhibitor)Small molecule | Breast CancerProstate Cancer HR+/HER2- Metastatic Breast Cancer | |
Dapagliflozin(Farxiga / Forxiga) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
| Approved | TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast CancerBladder / Urothelial Cancer HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma | |
| Approved | PD-L1Monoclonal antibody | Non-Small Cell Lung CancerOvarian CancerHepatocellular CarcinomaBladder CancerBiliary Tract CancerSmall Cell Lung CancerBladder / Urothelial CancerRenal Cell CarcinomaEndometrial Cancer Urothelial Carcinoma, Non-Muscle Invasive Bladder Cancer | |
Eplontersen(Wainua) | Approved | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy |
Discontinued programmes (8)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(227 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (8)
November 2026 (2)
December 2026 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (79)
January 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
April 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (3)
September 2027 (3)
What to watch
What to watch
October 2027 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (57)
January 2028 (4)
February 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2028 (3)
April 2028 (2)
What to watch
What to watch
May 2028 (4)
June 2028 (5)
July 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
November 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (50)
January 2029 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2029 (4)
What to watch
What to watch
What to watch
What to watch
March 2029 (4)
What to watch
What to watch
What to watch
April 2029 (3)
What to watch
What to watch
What to watch
May 2029 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2029 (4)
July 2029 (2)
August 2029 (4)
What to watch
What to watch
What to watch
What to watch
September 2029 (4)
What to watch
What to watch
What to watch
What to watch
October 2029 (2)
What to watch
What to watch
November 2029 (2)
December 2029 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (23)
January 2030 (1)
What to watch
February 2030 (2)
March 2030 (4)
April 2030 (2)
May 2030 (2)
What to watch
What to watch
June 2030 (2)
July 2030 (4)
What to watch
What to watch
What to watch
What to watch
September 2030 (4)
October 2030 (1)
What to watch
November 2030 (1)
What to watch
2031 (5)
2032 (2)
January 2032 (1)
December 2032 (1)
What to watch
2033 (2)
March 2033 (2)
Regulatory and conference events
(50)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 49 past events are shown.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $15.3B | $3.5B | $7.6B | — | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | $15.5B | $3.9B | $5.7B | — | report ↗ |
| 2025-Q3 | $15.2B | $3.7B | $8.2B | — | report ↗ |
| 2025-Q2 | $14.5B | $3.5B | $7.1B | — | report ↗ |
| 2025-Q1 | $13.6B | $3.2B | $5.4B | — | report ↗ |
| 2024-Q4 | $14.9B | $4.7B | $5.7B | — | report ↗ |
| 2024-Q3 | $13.6B | $3.1B | $4.9B | — | report ↗ |
| 2024-Q2 | $12.9B | $3.0B | $6.9B | — | report ↗ |
| 2024-Q1 | $12.7B | $2.8B | — | — | report ↗ |
| 2023-Q2 | $11.4B | $2.7B | $5.7B | — | report ↗ |
| 2022-Q2 | $10.8B | $2.5B | $4.8B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $58.7B | $14.2B | $5.7B | — | report ↗ |
AstraZeneca reported FY 2025 revenue of $58,739M, up 8.6% YoY, with R&D spend of $14,232M, up 4.8% YoY. Cash and equivalents stood at $5,741M, and the company reported net income of $10,233M.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($3K), 1 sale ($2.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Sharma Mani · See remarks | Award / grant | 1 | $186.24 | $186 | Form 4 |
| 2026-10-06 | Sharma Mani · See remarks | Award / grant | 2 | $159.80 | $320 | Form 4 |
| 2026-09-08 | Sharma Mani · See Remarks | Award / grant | 1 | $162.60 | $163 | Form 4 |
| 2026-08-08 | Sharma Mani · See Remarks | Open-market purchase | 20.233 | $160.57 | $3K | Form 4 |
| 2026-08-06 | Sharma Mani · SVP, Group Controller | Award / grant | 2 | $163.34 | $327 | Form 4 |
| 2026-07-06 | Sharma Mani · See Remarks | Award / grant | 2 | $190.43 | $381 | Form 4 |
| 2026-06-08 | Sharma Mani · See Remarks | Award / grant | 1 | $179.75 | $180 | Form 4 |
| 2026-05-20 | Sharma Mani · See Remarks | Open-market sale | 11,893 | $185.78 | $2.2M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,301 reporting institutions held 747.8M shares ($143.3B, 48.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | INVESTOR AB | 51,587,810 | $10.2B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 45,040,142 | $8.8B |
| 3 | Capital International Investors | 34,393,013 | $6.7B |
| 4 | FMR LLC | 29,601,724 | $5.8B |
| 5 | Capital World Investors | 28,264,580 | $5.5B |
| 6 | Legal & General Group Plc | 25,849,978 | $5.0B |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 23,751,085 | $4.6B |
| 8 | BANK OF AMERICA CORP /DE/ | 19,058,327 | $3.8B |
| 9 | VANGUARD ASSET MANAGEMENT, Ltd | 18,535,315 | $3.6B |
| 10 | JPMORGAN CHASE & CO | 18,590,922 | $3.6B |
| 11 | PRIMECAP MANAGEMENT CO/CA/ | 18,213,708 | $3.6B |
| 12 | FRANKLIN RESOURCES INC | 17,792,161 | $3.5B |
| 13 | PRUDENTIAL PLC | 16,506,300 | $3.2B |
| 14 | Amundi | 15,386,149 | $3.0B |
| 15 | VANGUARD FIDUCIARY TRUST CO | 13,195,178 | $2.6B |